304 related articles for article (PubMed ID: 28961959)
1. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
Hindryckx P; Vande Casteele N; Novak G; Khanna R; D'Haens G; Sandborn WJ; Danese S; Jairath V; Feagan BG
J Crohns Colitis; 2018 Jan; 12(1):105-119. PubMed ID: 28961959
[TBL] [Abstract][Full Text] [Related]
2. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
Bravatà I; Fiorino G; Allocca M; Repici A; Danese S
Scand J Gastroenterol; 2015 Jan; 50(1):113-20. PubMed ID: 25523561
[TBL] [Abstract][Full Text] [Related]
3. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
4. [Emerging Therapies: What Are Promising in the Near Future?].
Seo GS; Lee SH
Korean J Gastroenterol; 2018 Feb; 71(2):81-88. PubMed ID: 29471605
[TBL] [Abstract][Full Text] [Related]
5. Novel treatments for inflammatory bowel disease.
Lee HS; Park SK; Park DI
Korean J Intern Med; 2018 Jan; 33(1):20-27. PubMed ID: 29223139
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
[TBL] [Abstract][Full Text] [Related]
8. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
[TBL] [Abstract][Full Text] [Related]
9. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
Ehrenberg R; Griffith J; Theigs C; McDonald B
J Manag Care Spec Pharm; 2020 Jun; 26(6):758-765. PubMed ID: 32191593
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
11. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
15. Therapy of inflammatory bowel disease: what to expect in the next decade.
Leiman DA; Lichtenstein GR
Curr Opin Gastroenterol; 2014 Jul; 30(4):385-90. PubMed ID: 24902037
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
17. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases.
Reinglas J; Gonczi L; Kurt Z; Bessissow T; Lakatos PL
World J Gastroenterol; 2018 Aug; 24(32):3567-3582. PubMed ID: 30166855
[TBL] [Abstract][Full Text] [Related]
18. The role of integrin antagonists in the treatment of inflammatory bowel disease.
Beniwal-Patel P; Saha S
Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
20. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
